At a Glance
| Indication | Ulcerative colitis |
| Drug | CLD-423 |
| Mechanism of Action | TL1A and IL-23p19 inhibitor |
| Company | Caldera Therapeutics |
| Trial Phase | Phase 1 |
| Category | Corporate & Strategic |
| Sub Category | Merger Announced |
| Therapeutic Area | Gastroenterology & Hepatology |
| Target Company (Caldera) | Synlogic |
| Private Financing (Caldera) | $278 million |
| Initial Venture Funding (Caldera) | $112.5 million |
| Licensed From | Qyuns Therapeutics |
| Data Readout Expectation | End of 2026 |
| Funding Duration | Into 2029 |
| Acquiring Company (Vidya) | Processa Pharmaceuticals |
| Target Company (Vidya) | Vidya Therapeutics |
| Private Financing (Vidya) | $200 million |
| Drug Target (Vidya) | Bruton’s tyrosine kinase |
Caldera Therapeutics Merges with Synlogic, Secures $278M Funding
Caldera Therapeutics, launched seven months ago with $112.5 million in venture funding, has merged with Synlogic. Concurrently, it secured $278 million in private financing to support CLD-423, a drug licensed from Qyuns Therapeutics. CLD-423 targets TL1A and IL-23p19 for ulcerative colitis and Crohn's disease, with Phase 1 testing underway and data expected by the end of 2026. The merger and financing are expected to fund the company through Phase 2 development and operations into 2029.
- Caldera Therapeutics, a seven-month-old biotech, has merged with Synlogic and simultaneously raised $278 million in private financing. This significant capital infusion follows its initial $112.5 million venture funding, bolstering its financial position for future development.
- The financing will advance CLD-423, a drug licensed from China’s Qyuns Therapeutics, which targets the inflammatory proteins TL1A and IL-23p19. CLD-423 is currently in Phase 1 testing for ulcerative colitis and Crohn's disease, with initial data anticipated by the end of 2026.
- The combined merger and private financing are projected to fund Caldera through Phase 2 development of CLD-423. This strategic move provides a substantial financial runway, expected to support the company's operations until 2029.
Frequently Asked Questions
What are the 6 worst foods for ulcerative colitis?
For ulcerative colitis patients, particularly during flares, common trigger foods often include high-fiber items like raw fruits, vegetables, nuts, and seeds, as well as spicy foods that can irritate the gut mucosa. Other problematic categories are high-fat and fried foods, dairy products for those with lactose intolerance, alcohol, and caffeinated beverages, all of which can exacerbate gastrointestinal symptoms.
What is the strongest medication for ulcerative colitis?
While no single medication is universally deemed "the strongest" for ulcerative colitis, biologics and small molecule JAK inhibitors represent the most potent therapeutic options for moderate to severe and refractory disease. Biologics include TNF inhibitors (e.g., infliximab), integrin receptor antagonists (e.g., vedolizumab), and IL-12/23 inhibitors (e.g., ustekinumab). JAK inhibitors like tofacitinib and upadacitinib also offer high efficacy for inducing and maintaining remission. The choice of therapy depends on disease severity, patient history, and specific disease characteristics.
How close are we to curing ulcerative colitis?
Ulcerative colitis remains a chronic, incurable condition, with current therapeutic strategies focused on achieving and maintaining clinical and endoscopic remission. While novel biologics and small molecules have significantly improved patient outcomes and mucosal healing rates, they do not eradicate the underlying disease pathology. Research continues to explore disease mechanisms and develop more targeted interventions, but a definitive cure is not yet on the immediate horizon.
What is the standard of care for ulcerative colitis?
The standard of care for ulcerative colitis (UC) follows a step-up approach, primarily guided by disease severity, extent, and patient response. Initial therapy for mild-to-moderate disease often involves 5-aminosalicylates (5-ASAs). Moderate-to-severe cases typically require corticosteroids for induction, followed by immunomodulators (e.g., thiopurines) or advanced therapies for maintenance. Advanced therapies include biologics (e.g., TNF inhibitors, anti-integrins, IL-12/23 inhibitors) and small molecule JAK inhibitors, with colectomy reserved for refractory disease or complications.
What is the gold standard for ulcerative colitis?
Management of ulcerative colitis is highly individualized, thus there is no single "gold standard" treatment. For moderate-to-severe disease, advanced therapies such as biologics (e.g., anti-TNF, anti-integrin, IL-12/23 inhibitors) and small molecules (e.g., JAK inhibitors) represent the current standard of care. These agents aim to induce and maintain steroid-free remission and achieve mucosal healing.
Contact Us
📍
Address
One Research Ct, Suite 450
Rockville, MD 20850
✉️
For General Inquiry
info@pienomial.com
